🚀 Apply for £10k+ grants with our Startup Launch Kit
shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)

    PAR-24-147

    National Institutes of Health

    Opening date 6 Feb 2024, 12:00AM

    Closing date 4 Oct 2024, 12:00AM

    Funding Opportunity Number: PAR-24-147

    Opportunity Category: Discretionary

    CFDA Number(s): 93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders,93.866 -- Aging Research

    Cost Sharing or Matching Requirement: No

    Posted Date: Feb 06, 2024 12:00:00 AM EST

    Closing Date: Oct 04, 2024 12:00:00 AM EDT

    Award Ceiling: $500000

    Award Floor: none

    Eligible Applicants: Native American tribal organizations (other than Federally recognized tribal governments),County governments,Public housing authorities/Indian housing authorities,State governments,Native American tribal governments (Federally recognized),Public and State controlled institutions of higher education,For profit organizations other than small businesses,Small businesses,Others (see text field entitled "Additional Information on Eligibility" for clarification),Private institutions of higher education,Special district governments,Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,City or township governments,Independent school districts

    Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

    Agency Name: National Institutes of Health

    Description: This NOFO would support investigations with a minimum of two relevant co-pathologies (e.g., tau, alpha-synuclein, TDP-43, TMEM106B, vascular), with optional risk factors and co-morbidities, to identify cellular and molecular mechanisms of how/why multi-proteinopathy interactions drive worsening neurodegenerative processes and phenotypic outcomes. Studies should examine co-pathology cellular and molecular interactions across brain regions and time in proximate cell population, across various intracellular dynamics and localization, and upstream and downstream from aggregated protein states to determine what events lead to worse phenotypic outcomes.

    Grantor Contact Information: NIH Grants Information grantsinfo@nih.gov

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept